Literature DB >> 30806869

Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema.

Miho Nozaki1, Aki Kato2, Tsutomu Yasukawa2, Katsuya Suzuki2, Munenori Yoshida2, Yuichiro Ogura2.   

Abstract

PURPOSE: To evaluate the efficacy of indocyanine-green angiography (ICGA)-guided navigated focal laser photocoagulation for diabetic macular edema (DME). STUDY
DESIGN: Prospective, interventional case series.
METHODS: Six patients (8 eyes) were enrolled in this study. Fluorescein angiography (FA) and ICGA were performed using the Heidelberg Retina Angiogram 2 (Heidelberg Engineering). Navigated focal laser photocoagulation was delivered to the microaneurysms on ICGA using Navilas® (OD-OS GmbH, Germany). Central retinal thickness (CRT) and macular volume (MV) were measured by Cirrus HD-OCT (Carl Zeiss Meditec). At 6 months, the best-corrected visual acuity (BCVA), CRT and MV were compared to the values measured on day 0. The distances from the center of fovea to the closest microaneurysms (MAs) were measured on the pre-planned Navilas® image.
RESULTS: All eyes had previous treatment history. At 6 months, ICGA-guided navigated focal laser photocoagulation significantly reduced the CRT and the MV (p<0.05), and there was improvement in the BCVA (p<0.05). At 3 months, 5 out of the 8 eyes (63%) underwent additional ICGA-guided navigated focal laser photocoagulation due to remnants of MAs that had been confirmed by ICGA. There was no observed recurrence of edema after the ICGA-guided navigated focal laser photocoagulation during the 6-month follow-up. The mean distance from the center of fovea to the closest MAs was 624.8 ± 377.7 μm (range 336.0-1438.9 μm).
CONCLUSION: Our data suggest ICGA-guided navigated focal laser photocoagulation may be effective for the treatment of DME.

Entities:  

Keywords:  diabetic macular edema; focal laser photocoagulation; indocyanine green angiography; microaneurysm; navigated laser

Mesh:

Substances:

Year:  2019        PMID: 30806869     DOI: 10.1007/s10384-019-00662-x

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  5 in total

1.  Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.

Authors:  Kenichiro Mori; Shigeo Yoshida; Yoshiyuki Kobayashi; Keijiro Ishikawa; Shintaro Nakao; Toshio Hisatomi; Masatoshi Haruta; Tatsuro Isihibashi; Koh-Hei Sonoda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-21       Impact factor: 3.117

2.  Intraprocedural OCT monitoring of the immediate treatment response during indocyanine green angiography-guided laser therapy of teleangiectatic capillaries in diabetic macular edema.

Authors:  Felix Datlinger; Anja Datlinger; Andreas Pollreisz; Stefan Sacu; Ursula Schmidt-Erfurth; Peter Datlinger
Journal:  Sci Rep       Date:  2022-02-10       Impact factor: 4.379

3.  Regional Variety of Reduction in Retinal Thickness of Diabetic Macular Edema after Anti-VEGF Treatment.

Authors:  Yutaka Yamada; Yoshihiro Takamura; Takehiro Matsumura; Makoto Gozawa; Masakazu Morioka; Masaru Inatani
Journal:  Medicina (Kaunas)       Date:  2022-07-14       Impact factor: 2.948

Review 4.  Review of clinical studies and recommendation for a therapeutic flow chart for diabetic macular edema.

Authors:  Shigeo Yoshida; Tomoaki Murakami; Miho Nozaki; Kiyoshi Suzuma; Takayuki Baba; Takao Hirano; Osamu Sawada; Masahiko Sugimoto; Yoshihiro Takamura; Eiko Tsuiki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-09-30       Impact factor: 3.117

5.  Detection rate of diabetic macular microaneurysms comparing dye-based angiography and optical coherence tomography angiography.

Authors:  Martin Stattin; Anna-Maria Haas; Daniel Ahmed; Ulrike Stolba; Alexandra Graf; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.